45 CFR § 180 compliance
A · 100
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
33,813
Insurances with rates
11
CPT / HCPCS codes
11,033
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9150 | DAUNORUBICIN 20 MG INJ | $985,570 | $252,897 | $492,785 | $492,785 | 3 |
| J9150 | DAUNORUBICIN 20 MG INJ | $985,570 | $252,897 | $18.79 | $542,063 | 22 |
| 310362509 | KT IMPLANT HEARTMATE III 591420 | $431,676 | $110,768 | $107,919 | $176,987 | 4 |
| 310362509 | KT IMPLANT HEARTMATE III 591420 | $431,676 | $110,768 | $107,919 | $215,838 | 9 |
| J0223 | GIVOSIRAN 189MG/1ML SUBCUTANEOUS | $313,164 | $80,358 | $156,582 | $156,582 | 3 |
| J0223 | GIVOSIRAN 189MG/1ML SUBCUTANEOUS | $313,164 | $80,358 | $107 | $156,582 | 22 |
| J9347 | TREMELIMUMAB-ACTL 300MG/15ML INJ | $292,323 | $75,010 | $146,162 | $146,162 | 3 |
| J9347 | TREMELIMUMAB-ACTL 300MG/15ML INJ | $292,323 | $75,010 | $40,925 | $146,162 | 6 |
| J9228 | IPILIMUMAB 200MG INJ | $255,819 | $65,643 | $127,910 | $127,910 | 3 |
| J9228 | IPILIMUMAB 200MG INJ | $255,819 | $65,643 | $125 | $127,910 | 22 |
| 310325675 | CTRL PKT KT SEAL HRTMATE 452839 | $236,250 | $60,622 | $59,063 | $96,863 | 4 |
| 310325675 | CTRL PKT KT SEAL HRTMATE 452839 | $236,250 | $60,622 | $59,063 | $118,125 | 9 |
| 310334893 | KT IMP HVAD 435549 | $227,340 | $58,335 | $56,835 | $93,209 | 4 |
| 310334893 | KT IMP HVAD 435549 | $227,340 | $58,335 | $56,835 | $113,670 | 9 |
| 400021173 | MACI CELL PRODUCT 1 MEMBR 593957 | $224,684 | $57,654 | $56,171 | $92,120 | 4 |
| 400021173 | MACI CELL PRODUCT 1 MEMBR 593957 | $224,684 | $57,654 | $56,171 | $112,342 | 9 |
| 310361411 | HVAD STERILE 622250 | $219,124 | $56,227 | $54,781 | $89,841 | 4 |
| 310361411 | HVAD STERILE 622250 | $219,124 | $56,227 | $54,781 | $109,562 | 9 |
| J3357 | USTEKINUMAB SUBCUTANIOUS 90MG | $204,603 | $52,501 | $102,302 | $102,302 | 3 |
| J3357 | USTEKINUMAB SUBCUTANIOUS 90MG | $204,603 | $52,501 | $113 | $102,302 | 22 |
| 430605117 | VIEKIRA XR (200/33.33) TAB | $204,090 | $52,369 | — | — | 0 |
| 430605117 | VIEKIRA XR (200/33.33) TAB | $204,090 | $52,369 | $47.67 | $47.67 | 3 |
| 430608239 | RAVULIZUMAB-CWVZ 1100MG | $172,553 | $44,277 | $86,276 | $86,276 | 3 |
| 430608239 | RAVULIZUMAB-CWVZ 1100MG | $172,553 | $44,277 | $24,157 | $86,276 | 6 |
| 310359937 | IMPELLA 5.5 WITH SMARTASSIS | $164,000 | $42,082 | $41,000 | $67,240 | 4 |
| 310359937 | IMPELLA 5.5 WITH SMARTASSIS | $164,000 | $42,082 | $41,000 | $82,000 | 9 |
| J0638 | CANAKINUMAB 150MG(ILARIS)SC INJ | $148,598 | $38,130 | $74,299 | $74,299 | 3 |
| J0638 | CANAKINUMAB 150MG(ILARIS)SC INJ | $148,598 | $38,130 | $90.77 | $74,299 | 22 |
| J2350 | OCRELIZUMAB 300MG/10ML INJ VIAL | $144,871 | $37,174 | $72,436 | $72,436 | 3 |
| J2350 | OCRELIZUMAB 300MG/10ML INJ VIAL | $144,871 | $37,174 | $56.76 | $72,436 | 22 |
| 310357919 | IMPELLA 5.5 US 625934 | $140,000 | $35,924 | $35,000 | $57,400 | 4 |
| 310357919 | IMPELLA 5.5 US 625934 | $140,000 | $35,924 | $35,000 | $70,000 | 9 |
| 310334733 | SAPIEN 3 RESILIA W/COMM 20MM | $136,000 | $34,898 | $34,000 | $55,760 | 4 |
| 310334733 | SAPIEN 3 RESILIA W/COMM 20MM | $136,000 | $34,898 | $34,000 | $68,000 | 9 |
| 430605116 | VIEKIRA 28 DAY DOSE PACK | $135,090 | $34,664 | — | — | 0 |
| 430605116 | VIEKIRA 28 DAY DOSE PACK | $135,090 | $34,664 | $47.67 | $47.67 | 3 |
| 310325129 | KT SAPIEN 3 W COMM 23 536616 | $130,000 | $33,358 | $32,500 | $53,300 | 4 |
| 310325129 | KT SAPIEN 3 W COMM 23 536616 | $130,000 | $33,358 | $32,500 | $65,000 | 9 |
| 310330595 | STNT 31X8X15 TAG THOR 22F 669347 | $128,000 | $32,845 | $32,000 | $52,480 | 4 |
| 310330595 | STNT 31X8X15 TAG THOR 22F 669347 | $128,000 | $32,845 | $32,000 | $64,000 | 9 |
| 310332771 | IMP SYS PASCAL PRECSN | $122,400 | $31,408 | $30,600 | $50,184 | 4 |
| 310332771 | IMP SYS PASCAL PRECSN | $122,400 | $31,408 | $30,600 | $61,200 | 9 |
| J3245 | TILDRAKIZUMAB 100MG/1ML ILUMYA | $120,638 | $30,956 | $60,319 | $60,319 | 3 |
| J3245 | TILDRAKIZUMAB 100MG/1ML ILUMYA | $120,638 | $30,956 | $120 | $60,319 | 22 |
| 310324808 | VALVE AORTIC 26 535921 | $120,000 | $30,792 | $30,000 | $49,200 | 4 |
| 310324808 | VALVE AORTIC 26 535921 | $120,000 | $30,792 | $30,000 | $60,000 | 9 |
| 430604447 | USTEKINUMAB SUBCUTANEOUS 45MG | $102,302 | $26,251 | $51,151 | $51,151 | 3 |
| 430604447 | USTEKINUMAB SUBCUTANEOUS 45MG | $102,302 | $26,251 | $14,322 | $51,151 | 6 |
| 310325015 | IMPELLA CATH 5.0 383664 | $100,000 | $25,660 | $25,000 | $41,000 | 4 |
| 310325015 | IMPELLA CATH 5.0 383664 | $100,000 | $25,660 | $25,000 | $50,000 | 9 |
Showing top 50 of 33,813 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.